Targeted Delivery of Nanoparticles via Blood Vessels

Dear Colleagues,

The unique physicochemical and biological characteristics of nanomaterial/nanoparticle-based drug delivery systems are frequently utilized to increase the safety and therapeutic efficacy of encapsulated drugs by overcoming the primary limitations of conventional drug delivery systems, such as inadequate stability and solubility, lack of transmembrane transport, short circulation time and undesirable side effects. The successful advancement of nanotechnology in recent years, particularly the advent of novel nanomaterials, has yielded novel concepts and promising techniques, including targeted drug delivery toward the intended site of primary accumulation by combining therapeutic drugs with nanoparticles and targeting appropriate biological pathways. Nanoparticles have the potential to revolutionize strategies for treating vascular diseases through rational design of nano-based delivery systems for direct delivery to the bloodstream through the blood vessels, allowing for a more efficient delivery of drugs to their therapeutic target or even the diseased site, breaking down biological barriers and improving the drug's therapeutic index and particularly the development of balloon and stent delivery nanotechnologies for interventional vascular therapies. Additionally, advancements in molecular imaging have led to the emergence of the novel theranostic nanoparticles, which may carry both therapeutic and imaging properties. The field can expect significant advances in discovery, innovative technology and clinical translation over the next decade as we continue to strengthen the potential of nanotechnology for the treatment of vascular diseases. This Special Issue aims to include review and research articles that provide a comprehensive overview of the most recent attempts in the targeted delivery of nanoparticles in blood vessels and engineering of safer and more effective nanomedicines for clinical translation. 

Dr. Avishek Singh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanoparticle delivery
• transcellular transport
• vascular permeability
• nanoparticles
• endothelial cells